Molecularly Targeted Anti-Cancer Therapies

Tabs

Details

Basic Details

Date Posted:

Wednesday, January 24, 2018

Status:

Complete

Medical Product:

axitinib, bicalutamide, crizoatinib, dasatinib, erlotinib HCL, everolimus, gefitinib, imatinib mesylate, lapatinib ditosylate, nilotinib HCL, pazopanib HCL, ruxolitinib phosphate, sorafenib tosylate, sunitinib malate, tamoxifen citrate, vandetanib, vemurafenib, vismodegib

Description:

These reports look at the use of 18 selected generic drug products relating to molecularly targeted anti-cancer therapies in the Mini-Sentinel Distributed Database (MSDD). These results were generated using the Mini-Sentinel Distributed Query Tool. This query was run against the Dispensing Summary Table and distributed on May 10, 2013 to 17 Data Partners; this report includes information from 17 Data Partners.

Deliverables (2)

Mini-Sentinel Summary Table Report: Molecularly Targeted Anti-Cancer Therapies Report 1

Mini-Sentinel Summary Table Report: Molecularly Targeted Anti-Cancer Therapies Report 2

Additional Information

Additional Details

FDA Center:

CDER

Time Period:

2000 - 2012

Study Type:

Summary Table

Assessment Type:

Exploratory Analyses

Population / Cohort:

All individuals

Data Sources:

Mini-Sentinel Distributed Database (MSDD)

Search form

Assessments

Molecularly Targeted Anti-Cancer Therapies

Tabs